Evans A E, Anderson J R, Lefkowitz-Boudreaux I B, Finlay J L
Children's Hospital of Philadelphia, Pennsylvania, USA.
Med Pediatr Oncol. 1996 Jul;27(1):8-14. doi: 10.1002/(SICI)1096-911X(199607)27:1<8::AID-MPO3>3.0.CO;2-K.
In 1975, members of The Children's Cancer Group (CCG) initiated a trial for patients with infratentorial medulloblastomas and ependymomas. Patients, all of whom received post-operative cranio-spinal irradiation (CSI), were randomized to receive or not receive adjuvant chemotherapy (CT) with lomustine (CCNU), vincristine, and prednisone for 1 year. Thirty-six of the 42 patients with ependymoma entered on study were suitable for analysis; 22 received combined modality therapy and 14 irradiation (RT) alone. The failure-free survival (FFS) for the entire sample at 10 years is 36% and overall survival (OS) 39%, with no difference in outcomes between the two regimens. Survival was better for females (73%) than males (21%) and for those older than 10 years (51% vs. 31%). There were two toxic deaths in the group receiving CT. We conclude from this study with long-term follow-up that the CT used was not effective in improving the outcome in children with ependymoma.
1975年，儿童癌症研究组（CCG）的成员启动了一项针对幕下髓母细胞瘤和室管膜瘤患者的试验。所有患者均接受了术后全脑全脊髓照射（CSI），并被随机分为接受或不接受洛莫司汀（CCNU）、长春新碱和泼尼松辅助化疗（CT）1年。入组研究的42例室管膜瘤患者中有36例适合进行分析；22例接受了综合治疗，14例仅接受了放疗（RT）。整个样本10年无失败生存率（FFS）为36%，总生存率（OS）为39%，两种治疗方案的结果无差异。女性生存率（73%）高于男性（21%），10岁以上患者生存率（51%对31%）更高。接受CT治疗的组中有2例因毒性反应死亡。通过这项长期随访研究，我们得出结论，所使用的CT治疗对改善室管膜瘤患儿的预后无效。
